![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter and Conference Paper
Warfarin Underuse for Nonvalvular Atrial Fibrillation: How to Adjust Our Aims?
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice; its prevalence increases substantially with age, representing a growing epidemic with substantial effects on mortality and morbidity...
-
Chapter and Conference Paper
Anticoagulation Therapy of Atrial Fibrillation in the Elderly
The prevalence of atrial fibrillation (AF) increases substantially with age. The most recent data come from a cross-sectional study of adults in California, dealing with a population of 1.89 million [1]. The over...
-
Chapter and Conference Paper
Antiplatelet Agents for Prevention of Thromboembolism in Atrial Fibrillation: When, Why, and Which One?
Atrial fibrillation (AF) carries a high risk of systemic embolism, in particular stroke. This is true not only when AF is associated with valvular heart disease, but also in patients with nonvalvular AF, which...
-
Chapter
Prevention of Thromboembolism in Atrial Fibrillation: When Antiplatelet Agents and When Anticoagulants?
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice.